Skip to search formSkip to main contentSkip to account menu

TAK-441

Known as: 6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide, Smoothened Antagonist TAK-441 
An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

PyridinesPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
2015
2015
Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Purpose: This first-in-human study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical… 
2013
2013
Abstract 4952: A novel smoothened antagonist, TAK-441, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Hedgehog (Hh) signaling is a highly conserved inter- and intracellular communication mechanism that governs organogenesis and is… 
2013
2013
325 TAK-441, A NOVEL INVESTIGATIONAL SMOOTHENED ANTAGONIST, DELAYS CASTRATION RESISTANT PROGRESSION IN PROSTATE CANCER BY DISRUPTING PARACRINE HEDGEHOG SIGNALING
2011
2011
Abstract 2823: TAK-441, a novel investigational small molecule hedgehog pathway inhibitor for use in cancer therapy
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Dysregulation of hedgehog (Hh) signal, which is caused… 
2011
2011
Abstract 4508: Nonclinical pharmacokinetics of TAK-441, a hedgehog pathway inhibitor
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL TAK-441 is a potent and selective smoothened (Smo… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)